Objective To review the comparative effectiveness of osteoporosis treatments, including the
bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in …

Bone fragility is a major health concern, as the increased risk of bone fractures has
devastating outcomes in terms of mortality, decreased autonomy, and healthcare costs …

Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A
Clinical Practice Guideline Update From the American College of Physicians | Annals of Internal …

Background Unlike most chronic diseases, osteoporosis treatments are generally limited to
a single drug at a fixed dose and frequency. Nonetheless, no approved therapy is able to …

Background The validation of bone mineral density (BMD) as a surrogate outcome for
fracture would allow the size of future randomised controlled osteoporosis registration trials …

European guidance for the diagnosis and management of osteoporosis in postmenopausal
women | Osteoporosis International Skip to main content SpringerLink Account Menu Find a …

Guidance is provided in a European setting on the assessment and treatment of
postmenopausal women at risk from fractures due to osteoporosis. Introduction The …

Background Osteoporosis medications increase bone-mineral density (BMD) and lower but
do not eliminate fracture risk. The combining of anabolic agents with bisphosphonates has …

Background: Osteoporosis is a major contributor to the propensity to fracture among older
adults, and various pharmaceuticals are available to treat it. Purpose: To update a review …

A guidance on the assessment and treatment of postmenopausal women at risk from
fractures due to osteoporosis was recently published in Osteoporosis International as a joint …